openPR Logo
Press release

T-Cell Immunotherapy Market worth $17.17 billion by 2030, growing at a CAGR of 14.03% - Exclusive Report by 360iResearch

10-26-2023 09:36 AM CET | Health & Medicine

Press release from: 360iResearch

T-Cell Immunotherapy Market | 360iResearch

T-Cell Immunotherapy Market | 360iResearch

The "T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

Request Sample Copy of this Report @ https://www.360iresearch.com/library/intelligence/t-cell-immunotherapy?utm_source=openpr&utm_medium=referral&utm_campaign=sample

Market Segmentation & Coverage:

This research report categorizes the T-Cell Immunotherapy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Mechanism Of Action, market is studied across Active Immunotherapy and Passive Immunotherapy. The Passive Immunotherapy is projected to witness significant market share during forecast period.

Based on Product Class, market is studied across Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy. The Oncolytic Virus Therapy is projected to witness significant market share during forecast period.

Based on Type of Therapy, market is studied across CAR-T, TCR, and TIL. The TIL is projected to witness significant market share during forecast period.

Based on Indication, market is studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma. The Liver Cancer is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas is projected to witness significant market share during forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the T-Cell Immunotherapy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the T-Cell Immunotherapy Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the T-Cell Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Alaunos Therapeutics, Inc., Apac Biotech, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Cellectis SA, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Inc., Gilead Sciences, Inc., Green Cross Corporation, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Inc., LAVA Therapeutics N.V., Lyell Immunopharma, Inc., Neogene Therapeutics, Inc., NeoTX Therapeutics Ltd., Novartis AG, Oxford Vacmedix UK Limited, Poseida Therapeutics, Inc., TScan Therapeutics, Inc., and Xenetic Biosciences, Inc..

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. T-Cell Immunotherapy Market, by Mechanism Of Action
7. T-Cell Immunotherapy Market, by Product Class
8. T-Cell Immunotherapy Market, by Type of Therapy
9. T-Cell Immunotherapy Market, by Indication
10. Americas T-Cell Immunotherapy Market
11. Asia-Pacific T-Cell Immunotherapy Market
12. Europe, Middle East & Africa T-Cell Immunotherapy Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the T-Cell Immunotherapy Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the T-Cell Immunotherapy Market?
3. What is the competitive strategic window for opportunities in the T-Cell Immunotherapy Market?
4. What are the technology trends and regulatory frameworks in the T-Cell Immunotherapy Market?
5. What is the market share of the leading vendors in the T-Cell Immunotherapy Market?
6. What modes and strategic moves are considered suitable for entering the T-Cell Immunotherapy Market?

Read More @ https://www.360iresearch.com/library/intelligence/t-cell-immunotherapy?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release T-Cell Immunotherapy Market worth $17.17 billion by 2030, growing at a CAGR of 14.03% - Exclusive Report by 360iResearch here

News-ID: 3264034 • Views:

More Releases from 360iResearch

Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Global Treatment Demand
Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Globa …
In recent years, the silent ascent of human metapneumovirus (HMPV) infections has begun to capture significant attention within the realm of infectious diseases. As we advance in medical science, unraveling complexities of age-old pathogens like common influenza or emerging illnesses like COVID-19, a critical discourse has been emerging around HMPV. Particularly, there seems to be a burgeoning acknowledgment of its growing impact on vulnerable global populations, propelling an increased demand
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and expected to reach USD 10.06 billion in 2024, at a CAGR 7.63% to reach USD 15.71 billion by 2030.
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and …
From Appetite to Advocacy: The Rising Demand for Meat Alternatives In recent years, the global food industry has been undergoing a remarkable transformation, driven primarily by an increasing consumer demand for healthier, sustainable, and ethically sourced food products. This seismic shift has brought traditional meat alternatives and high-protein plant-based foods into the spotlight. As the world becomes more conscious of the implications of meat consumption on health and the environment, the
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 2023 and expected to reach USD 292.84 billion in 2024, at a CAGR 11.08% to reach USD 552.63 billion by 2030.
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 202 …
Unpacking the Surge in Investments and Collaborations to Bolster Mobility-as-a-Service In recent years, as urban landscapes continually evolve, a transformative shift known as Mobility-as-a-Service (MaaS) has reshaped the way we perceive transportation. Marked by the integration of various forms of transport services into a single accessible on-demand mobility solution, MaaS is rapidly gaining traction across global cities. As an emerging paradigm, it's not just shaping the future of travel but also
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 and expected to reach USD 62.23 billion in 2024, at a CAGR 9.99% to reach USD 110.34 billion by 2030.
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 …
Smart City Revolutions: Why Data Center Colocation is the Future Backbone In the era of digital transformation, urban landscapes across the globe are undergoing a seismic shift toward becoming "smart cities." The concept of a smart city revolves around using digital technology, IoT (Internet of Things), AI, and data analytics at an unprecedented scale to improve urban infrastructure, manage resources efficiently, and enhance the quality of life for citizens. A vital

All 5 Releases


More Releases for Immunotherapy

Immunotherapy Drugs Market
Immunotherapy Drugs Market Size reached US$ 288.02 Billion in 2024 and is expected to reach US$ 872.64 Billion by 2033, growing at a CAGR of 13.2% during the forecast period 2025-2033. The Immunotherapy Drugs Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead
Anti TIGIT Antibodies Revolutionizing Immunotherapy
Anti-TIGIT antibodies are at the forefront of a revolution in immunotherapy, representing a new class of immune checkpoint inhibitors that have the potential to transform the treatment landscape for cancer. Immunotherapy, which harnesses the body's immune system to fight cancer, has already made significant strides with the introduction of PD-1, PD-L1, and CTLA-4 inhibitors. However, the discovery and development of anti-TIGIT antibodies add a new dimension to this field, offering
Allergy Immunotherapy Market Combating the Rising Tide: The Allergy Immunotherap …
Allergy Immunotherapy Market is to reach over USD 4.01 billion by the year 2031 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Allergy Immunotherapy Market Size, Share & Trends Analysis Report By Treatment Type (SCIT, SLIT), By Allergy Type (Allergic Rhinitis, Asthma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Region, Market Outlook And Industry Analysis
Allergy Immunotherapy Market - Empowering Resilience, Defying Allergies: Advanci …
Newark, New Castle, USA - new report, titled Allergy Immunotherapy Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Allergy Immunotherapy market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Allergy Immunotherapy market. The report offers an overview of the market, which
Cancer Immunotherapy Market Cancer Immunotherapy Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Immunotherapy: Mending Cancer Regimens 1.1 Preface to Cancer Immunotherapy 1.2 Evolution of Cancer Immunotherapy 2. Categorization of Cancer Immunotherapy 2.1 Specific Cancer Immunotherapy 2.1.1 Cancer Vaccines 2.1.2 Monoclonal Antibodies 2.2 Non-Specific Cancer Immunotherapy 2.2.1 Adoptive Cell Transfer Immunotherapy 2.2.2 Immune Checkpoint Inhibitors 3. Fundamentals
Global Cancer Immunotherapy Market & Cancer Immunotherapy Clinical Trials Outloo …
Pharmaceutical companies are actively engaged in research and development of cancer immunotherapies because of large unmet medical necessities. Investigators are trying to come forth with innovative cancer immunotherapeutic products having high safety and efficacy profiles which are not offered by conventional therapeutics. Higher investments in research and development segment could significantly increase the drug discovery rates which will alleviate the medical condition of cancer patients. Simultaneously, technological advancements are being